Section 5 of 6
Economic information and modeling report
1 evidence topic · 2 sources
Modeling overview
Summary
The economic evidence in this report concerns the disease and comparator treatment pathways. A systematic review reported average metastatic colorectal cancer treatment costs ranging from $12,346 to $293,461 across heterogeneous studies. A separate analysis of 82 participants used a US Medicare payer perspective and reported an incremental cost-effectiveness ratio of US$518,000 per quality-adjusted life-year gained. These figures do not estimate the acquisition cost, cost effectiveness, or budget impact of zanzalintinib.
Zanzalintinib-specific health technology assessment
No evidence found.
Zanzalintinib-specific acquisition price, annual treatment cost, price corridor, cost-effectiveness analysis, and budget-impact results
No evidence found.
Public zanzalintinib-specific economic model
No evidence found.
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.